

TauRx gets recognition as a Technology Innovation Leader

11 June 2019 | News

TauRx has been recognized for its Visionary Innovation, in "developing novel treatments for neurodegenerative disease"



Singapore headquartered TauRx, a leader in neurodegenerative disease research, received the Frost & Sullivan's 2019 Asia Pacific Neurodegenerative Disease Management Technology Innovation Award.

The Award, part of ongoing research and independent analysis by global growth partnership company Frost & Sullivan to identify companies whose above average industry growth is enabled through consistent pursuit or investment in new technologies, recognizes the positive outcomes of TauRx's tau-focused research and credits the company's work in the following areas:

- **Industry Impact:** Recognition of TauRx's commitment in improving Alzheimer's treatment. Notably, that its rembel® and LMTX® products have pioneered the clinical development of tau aggregation inhibitors as a novel approach to treat the disease.
- **Product Impact:** The Award notes TauRx's fruitful research into tau aggregation inhibition as a basis for developing drugs that target a range of neurodegenerative diseases of the brain sharing a similar pathology.
- **Application Diversity:** Acknowledgement of TauRx's efforts in developing easy-to-administer tools using widely available, low-cost delivery methods that can detect, diagnose and track the spread of neurodegenerative disease in the brain.

Through the Award, TauRx has been recognized for its Visionary Innovation, in "developing novel treatments for neurodegenerative disease" and is credited with the indication that the company's low-cost therapeutic and diagnostic Alzheimer's solutions are "poised to revolutionize the market." TauRx scored an average rating of Excellent (9.5) on Frost & Sullivan's Decision Support Scorecard for Technology Innovation, with individual category scores of 9.5 for both Future Business Value and Technology Attributes, against competitor scores of 7.

"While this Award is a credit to TauRx, it also supports and reinforces the need and opportunity for continued research efforts

by the neurodegenerative disease management industry for the benefit of patients, researchers and healthcare practitioners in Asia Pacific and beyond," said Prof. Claude Wischik, Executive Chairman and co-founder of TauRx and Professor of Old Age Psychiatry at the University of Aberdeen.

TauRx continues its program of research in Alzheimer's with its new clinical trial, named LUCIDITY.